#### Practical advice on using Al and machine learning on omics data



National University of Singapore


#### Wong Limsoon

© Copyright National University of Singapore. All Rights Reserved.

## We focus only on knowledge discovery & classifier learning here...


Copyright © 2019 by National University of Singapore. All Rights Reserved

#### What is classifier learning?



#### What is classifier learning?









#### Question: Can you explain how?

#### **Classifier learning**


Learn from past experience, and use the learned knowledge to classify new data

Knowledge learned by intelligent algorithms

**Examples** 

*Clinical diagnosis for patients* 

Cell type classification




#### Key steps of learning a classifier

Training data gathering

Feature generation *k-grams, colour, texture, ...* 

Feature selection *Entropy, χ2, CFS, t-test, ...* 



Feature integration by machine learning *SVM, ANN, PCL, CART, C4.5, kNN, ...* 

#### Data

Classification application involves > 1 class of data *Normal vs disease cells for a diagnosis problem* 

Training data is a set of instances (samples, points, etc.) with known class labels

Test data is a set of instances whose class labels are to be predicted

Outlook	Temp	Humidity	Windy	class
Sunny	75	70	true	Play
Sunny	80	90	true	Don't
Sunny	85	85	false	Don't
Sunny	72	95	true	Don't
Sunny	69	70	false	Play
Overcast	72	90	true	Play
Overcast	83	78	false	Play
Overcast	64	65	true	Play
Overcast	81	75	false	Play
Rain	71	80	true	Don't
Rain	65	70	true	Don't
Rain	75	80	false	Play
Rain	68	80	false	Play
Rain	70	96	false	Play

#### Features (aka attributes)

#### Categorical features *Outlook, windy*

Continuous or numerical features

Temp, humidity


Discretization

Outlook	Temp	Humidity	Windy	class
Sunny	75	70	true	Play
Sunny	80	90	true	Don't
Sunny	85	85	false	Don't
Sunny	72	95	true	Don't
Sunny	69	70	false	Play
Overcast	72	90	true	Play
Overcast	83	78	false	Play
Overcast	64	65	true	Play
Overcast	81	75	false	Play
Rain	71	80	true	Don't
Rain	65	70	true	Don't
Rain	75	80	false	Play
Rain	68	80	false	Play
Rain	70	96	false	Play

### **Feature selection**

Copyright © 2019 by National University of Singapore. All Rights Reserved.

#### **Basic idea of feature selection**



Choose features that have high inter-class distance and low intra-class distance

g. t-statistic 
$$t = \frac{|\mu_1 - \mu_2|}{\sqrt{(\sigma_1^2/n_1) + (\sigma_2^2/n_2)}}$$

Ε.

#### Food for thought



Original photographer unknown/ See also www.cs.gmu.edu/~jessica/DimReducDanger.htm

© Eamonn Keogh

# Machine learning methods

Copyright © 2019 by National University of Singapore. All Rights Reserved.

Popular machine learning methods K-nearest neighbor (kNN)

Support vector machines (SVM)

Naïve Bayes

Neural networks


Decision trees & many more...


WEKA is a nice free package for classifier learning

of Waikato

#### **Decision tree**

Outlook	Temp	Humidity	Windy	class
Sunny	75	70	true	Play
Sunny	80	90	true	Don't
Sunny	85	85	false	Don't
Sunny	72	95	true	Don't
Sunny	69	70	false	Play
Overcast	72	90	true	Play
Overcast	83	78	false	Play
Overcast	64	65	true	Play
Overcast	81	75	false	Play
Rain	71	80	true	Don't
Rain	65	70	true	Don't
Rain	75	80	false	Play
Rain	68	80	false	Play
Rain	70	96	false	Play





#### **Decision tree construction**

Select the "best" feature as root node of the whole tree

Partition dataset into subsets using this feature so that the subsets are as "pure" as possible

After partition by this feature, select the best feature (wrt the subset of training data) as root node of this sub-tree

Recursively, until the partitions become pure or almost pure

#### **Ensemble classifier**


 $h_1$ ,  $h_2$ ,  $h_3$  are indep classifiers w/ accuracy = 60%  $C_1$ ,  $C_2$  are the only classes t is a test instance in  $C_1$  $h(t) = argmax_{C \in \{C1, C2\}} |\{h_i \in \{h_1, h_2, h_3\} | h_i(t) = C\}|$ Then prob(h(t) =  $C_1$ )  $= \text{prob}(h_1(t)=C_1 \& h_2(t)=C_1 \& h_3(t)=C_1) +$  $prob(h_1(t)=C_1 \& h_2(t)=C_1 \& h_3(t)=C_2) +$  $prob(h_1(t)=C_1 \& h_2(t)=C_2 \& h_3(t)=C_1) +$  $prob(h_1(t)=C_2 \& h_2(t)=C_1 \& h_3(t)=C_1)$ = 60% \* 60% \* 60% + 60% \* 60% \* 40% +60% \* 40% \* 60% + 40% \* 60% \* 60% = 64.8%




#### Given a new case

Find k "nearest" neighbours, i.e., k most similar points in the training data set

Assign new case to the same class to which most of these neighbours belong



#### **Neural networks**



 $y = f\left(\sum_{j} w_{j} f\left(\sum_{i} x_{i} v_{ij}\right)\right)$ 

### Classifier assessment

# Common assessment measures

Accuracy


Sensitivity

Specificity

Precision

**ROC** curves

	predicted	predicted
	as positive	as negative
positive	TP	FN
negative	FP	TN



#### Food for thought

You have a classifier. On a test set having 20% +ve and 80% -ve cases, the classifier's recall and precision are both 80%


Suppose you test it on a new test set having 80% +ve and 20% -ve cases. What do you expect its accuracy to be?

You may assume that the +ve (resp. –ve) cases in both test sets are equally sufficiently representative of the +ve (resp. –ve) real-world population

#### What lesson have you learned?


Copyright © 2019 by National University of Singapore. All Rights Reserved.

#### Estimating accuracy of classifier learning



during "Build Classifier"

#### **Cross validation**



#### Food for thought

What is the logical basis of cross validation? *Hint: Central limit theorem* 

What / whose accuracy does it really estimate?

### An old example

Copyright © 2019 by National University of Singapore. All Rights Reserved.

#### Childhood ALL

Major subtypes: T-ALL, E2A-PBX, TEL-AML, BCR-ABL, MLL genome rearrangements, Hyperdiploid>50

Diff subtypes respond differently to same treatment

... Match treatment to subtype

Conventional diagnosis Immunophenotyping Cytogenetics Molecular diagnostics

Can gene expression profiling be used to replace all these? Childhood ALL subtype diagnosis by classifier learning


Gene expression data collection

Gene selection by  $\chi 2$ 

**Classifier training** 

Apply classifier for diagnosis of future cases

#### Childhood ALL subtype diagnosis workflow



Paired datasets	Ingredients	Training	Testing
T-ALL vs	0	28  vs  187	0
	$OTHERS1 = \{E2A-PBX1, TEL-AML1,$	20 VS 107	15 VS 97
OTHERS1	BCR-ABL, Hyperdip>50, MLL, OTHERS}		
E2A-PBX1 vs	$OTHERS2 = \{TEL-AML1, BCR-ABL$	$18\ \mathrm{vs}\ 169$	9 vs 88
OTHERS2	Hyperdip>50, MLL, OTHERS}		
TEL-AML1 vs	$OTHERS3 = \{BCR-ABL$	$52~\mathrm{vs}~117$	$27 \ \mathrm{vs} \ 61$
OTHERS3	Hyperdip>50, MLL, OTHERS}		
BCR-ABL vs	$OTHERS4 = \{Hyperdip > 50,$	9 vs 108	6 vs 55
OTHERS4	MLL, OTHERS}		
MLL vs	$OTHERS5 = \{Hyperdip > 50, OTHERS\}$	$14 \ \mathrm{vs} \ 94$	6 vs 49
OTHERS5			
Hyperdip>50 vs	$OTHERS = \{Hyperdip47-50, Pseudodip, \}$	$42~\mathrm{vs}~52$	22  vs  27
OTHERS	Hypodip, Normo}		

#### Accuracy of various classifiers

Testing Data	Error rate of different models			
	C4.5	SVM	NB	PCL
T-ALL vs OTHERS1	0:1	0:0	0:0	0:0
E2A-PBX1 vs OTHERS2	0:0	0:0	0:0	0:0
TEL-AML1 vs OTHERS3	1:1	0:1	0:1	1:0
BCR-ABL vs OTHERS4	2:0	3:0	1:4	2:0
MLL vs OTHERS5	0:1	0:0	0:0	0:0
Hyperdiploid $>50$ vs OTHERS	2:6	0:2	0:2	0:1
Total Errors	14	6	8	4

The classifiers are all applied to the 20 genes selected by  $\chi 2$  at each level of the tree

# Don't worry about small differences in accuracy etc.

# These differences are meaningless

Copyright © 2019 by National University of Singapore. All Rights Reserved.


## More important to figure out whether you have learned a meaningful classifier that is robust

#### A recent story

		MetaMap		Our Method	
	Disease	Precision / Recall /	F1-score	Precision / Recall / F1-score	
			penI	1100101011100001711100010	
	Atelectasis	87.3 / 96.5 /	91.7	88.7 / 96.5 / 92.4	
	Cardiomegaly	100.0/ 85.5/	92.2	100.0 / 85.5 / 92.2	
	Effusion	90.3 / 87.5 /	88.9	96.6 / 87.5 / 91.8	
	Infiltration	68.0 / 100.0 /	81.0	81.0 / 100.0 / 89.5	
	Mass	100.0 / 66.7 /	80.0	100.0 / 66.7 / 80.0	
	Nodule	86.7 / 65.0 /	74.3	82.4 / 70.0 / 75.7	
	Pneumonia	40.0 / 80.0 /	53.3	44.4 / 80.0 / 57.1	
	Pneumothorax Copertion 6	6.7/ 90.9/	76.9	°00/6.57.1/ 66.7 82.4	
التحر	na 9	4.1/ 64.0/	76.2	94.1 / 64.0 /	
Jrosis	10	0.0 / 100.0 /	100.0	100.0 / 100.0 /	100.
PT	10	0.0/ 75.0/	85.7	100.0 / 75.0 /	85.7
Hernia	10	0.0 / 100.0 /	100.0	100.0 / 100.0 /	100.0
Total	7	7.2/ 84.6/	80.7	89.8 / 85.0 /	87.3
		ChestX	-ray14		
Atelectasis	s 8	8.6/ 98.1/	93.1	96.6/ 97.3/	96.9
ardiomeg	galy 9	4.1/ 95.7/	94.9	96.7/ 95.7/	96.2
ion		7.7/ 99.6/	93.3	94.8/ 99.2/	r
	6	9.7/ 90.0/	78.6	95.9/ 85.6.2	
	Pneumonia			01.5/ 88.1	
				2 110 1 2 010 1 2 010	
	Pneumonia Pneumothorax Consolidation Edema Emphysema Fibrosis PT Hernia <i>Total</i>	87.47 100.07 72.87 98.37 72.17 93.97 97.67 93.27 84.67 100.07 85.17 97.67 66.77 100.07 82.87 95.57	93.3 83.7 81.6 95.3 91.7 90.9 80.0 88.7	94.3 / 98.8 / 96.5 95.2 / 98.3 / 96.7 96.9 / 93.9 / 95.43 100.0 / 90.9 / 95.2 91.7 / 100.0 / 95.7 97.6 / 97.6 / 97.6 100.0 / 100.0 / 100.0 94.4 / 94.4 / 94.4	

### Really good results from a study published in CVPR 2017


Copyright © 2019 by National University of Singapore. All Rights Reserved.



Actually the dataset contained many mis-labeled or biased data Biased data – many pneumo-thorax cases were patients treated with chest drain Will a classifier learned from yesterday's samples work well on tomorrow's samples?

Samples from diff batches are grouped together, regardless of subtypes and treatment response

Sometimes, a gene expression study may involve batches of data collected over a long period of time... Time Span of Gene Expression Profiles







Image credit: Difeng Dong's PhD dissertation, 2011

Copyright © 2019 by National University of Singapore. All Rights Reserved.


# Accuracy does not correlate with classifier similarity

NN	NN Acc. (%)	Acc. $t_1$ -sparse (%)	Acc. t <sub>2</sub> -sparse (%)	NPAQ r for $t_1$ -sparse (%)	NPAQ r for t <sub>2</sub> -sparse (%)
ARCH1	74.00	78.00	81.00	20.31	62.50
ARCH <sub>2</sub>	62.00	73.00	78.00	12.50	65.62
$\operatorname{ARCH}_3$	76.00	82.00	83.00	4 Although t2	2-sparse and ARCH7 are b
ARCH <sub>4</sub>	50.00	64.00	72.00		rate on the test set, they
ARCH5	78.00	82.00	83.00	7 disagree	e on ~80% of future cases
ARCH <sub>6</sub>	80.00	11.00	87.00	37.50	55.4
ARCH <sub>7</sub>	87.00	89.00	89.00	6.25	79.69

Table 2: First and second column refer to the baseline model where we use BNNs with 7 different architectures. The third and fourth represent the accuracies of sparsified models with  $t_1 = 0.03, t_2 = 0.05$  sparsification thresholds. The last 2 columns show NPAQ estimates for the difference between each sparsified model and the orignal model. Features used by a prediction model are crucial for understanding the model and assessing its soundness




# High accuracy does not imply features used are reproducible



Agreement of feature sets selected from different samples of the same population is much poorer for methods that use no or "wrong" domain knowledge (SP, HE)

Goh & Wong. JBCB, 14(5):1650029, 2016.

# High accuracy does not imply features used are "meaningful"



Features selected from different samples of the same population is much more unstable for methods that use no or "wrong" domain knowledge (SP, HE)

Goh & Wong. JBCB, 14(5):1650029, 2016.

# High accuracy does not imply features used are better than random

	ET/FSNET/PFSNET/PPFSNET uses h features (complexes) but correct hypothesis/distribution		CV p-val 0.91	CV accuracy/pval 1.08
HE	162	0.98	0.91	1.08
SNET	21	0.84	0.06	14.00
FSNET	36	0.96	0.06	16.00
PFSNET	65	0.92	0.06	15.33
PPFSNET	66	0.96	0.06	16.00

Classifiers trained on feature sets selected by SP, HE, etc. all have high accuracy

But they (SP/HE) may be confounded and result in classifiers not better than classifiers trained on comparable random feature sets of the same size

Goh, & Wong. Proteomics, 17(10):1700093, 2017


# Some lessons from breast cancer survival signatures

Copyright © 2019 by National University of Singapore. All Rights Reserved

#### Breast cancer survival signatures

40-50% of random signatures also have pvalue << 0.05

Significant signatures may be confounded; they are no better than random ones!



#### Food for thought

For any independent breast cancer survival dataset, a random signature has ~50% chance to be significant in it


How many independent datasets are needed to avoid reporting random signatures as significant?

n	(50%) <sup>n</sup>
1	50.00%
2	25.00%
3	12.50%
4	6.25%
5	3.13%
6	1.60%
7	0.78%

#### **Test on 7 datasets**

SPS & most known signatures are universally significant on 7 breast cancer datasets

Random signatures (same size as SPS) are hardly universal, even though they get better p-values than known signatures on some datasets



Goh & Wong. Drug Discovery Today, 24(1):31--36, 2019

#### Food for thought


40-50% of random signatures are significant in 1 dataset

Red histogram is expected # of random signatures significant in 1 to 7 independent dataset

Frequency

Blue histogram is observed distribution

What does this figure tell?



Number of datasets random signature significant in

#### Learning points

Many machine learning methods

Most methods give similar good results, when provided the same *informative* features

Accuracy etc. are too simple minded for assessing whether a prediction model is good

Validate on many datasets

Some independent datasets are *not* as independent as you think

#### References

Li, et al. Data mining techniques for the practical bioinformatician. *The Practical Bioinformatician*, Chapter 3, pages 35-70, World Scientific, 2004

Li, et al. Simple rules underlying gene expression profiles of more than six subtypes of acute lymphoblastic leukemia (ALL) patients. *Bioinformatics*. 19:71-78, 2003

Goh & Wong. **Dealing with confounders in omics analysis**. *Trends in Biotechnology*, 36(5):488-498, 2018

Goh & Wong. Why breast cancer signatures are no better than random signatures explained. *Drug Discovery Today*, 23(11):1818-1823, 2018

Goh & Wong. Turning straw into gold: Building robustness into gene signature inference. *Drug Discovery Today*, 24(1):31-36, 2019